384
Participants
Start Date
November 5, 2014
Primary Completion Date
January 17, 2017
Study Completion Date
January 17, 2017
Ranibizumab (RFB002)
Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
Laser
Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
Sham injection
Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
Sham laser
Imitation of an active laser
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Harbin
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Wenzhou
Novartis Investigative Site, Nanchang
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Shantou
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Qingdao
Novartis Investigative Site, Wuxi
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY